Anti-HDV IgM as a marker of disease activity in hepatitis delta.

Hepatitis delta frequently leads to liver cirrhosis and hepatic decompensation. As treatment options are limited, there is a need for biomarkers to determine disease activity and to predict the risk of disease progression. We hypothesized that anti-HDV IgM could represent such a marker.Samples of 12...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Anika Wranke, Benjamin Heidrich, Stefanie Ernst, Beatriz Calle Serrano, Florin Alexandru Caruntu, Manuela Gabriela Curescu, Kendal Yalcin, Selim Gürel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George V Papatheodoridis, Birgit Bremer, Judith Stift, Jan Grabowski, Janina Kirschner, Kerstin Port, Markus Cornberg, Christine S Falk, Hans-Peter Dienes, Svenja Hardtke, Michael P Manns, Cihan Yurdaydin, Heiner Wedemeyer, HIDIT-2 Study Group
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Public Library of Science (PLoS) 2014-01-01
Rangatū:	PLoS ONE
Urunga tuihono:	http://europepmc.org/articles/PMC4114528?pdf=render
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Anti-HDV IgM as a marker of disease activity in hepatitis delta.

Ngā tūemi rite